Key result
Vitamin D3 supplementation significantly improves biomarkers and functional capacity in heart failure patients.
The aim of the present study was to investigate whether vitamin D supplementation could improve biochemical findings and functional capacity of patients with heart failure (HF). One hundred patients with New York Heart Association (NYHA) class I through III HF were included in this prospective study and their 25-hydroxyvitamin D levels were evaluated. Only 6% of the participants had a sufficient serum concentration of 25(OH) D >30 nmol/L. Patients with insufficient or deficient serum levels of 25(OH) D (<30 ng/mL and <20 ng/mL, respectively) received oral vitamin D3 (cholecalciferol) for a total period of 4 months. Vitamin D supplementation increased mean serum concentration of 25(OH) D from 12.63±7.60 nmol/L to 54.49±18.01 nmol/L (P<.001). After vitamin D supplementation, the serum level of pro-brain natriuretic peptide markedly decreased (P<.001). Cholecalciferol significantly decreased high-sensitivity C-reactive protein level (P<.001). Restoration of serum 25(OH) D level was also associated with substantial improvement in NYHA class (P<.001) and 6-minute walk distance (P<.001).
No takes yet. Share an insight, caveat, or question.
Amin et al. (2013) studied Congestive Heart Failure (NYHA class I through III) (n=100). Oral vitamin D3 (cholecalciferol) was evaluated on Biochemical findings (serum 25(OH)D, pro-BNP, hs-CRP) and functional capacity (NYHA class, 6-minute walk distance) (p=<.001). Oral vitamin D3 supplementation in heart failure patients increased serum 25(OH)D from 12.63 to 54.49 nmol/L and significantly improved pro-BNP, hs-CRP, NYHA class, and 6-minute walk distance (all P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: